Table 2.
Incidence rates before and after the introduction of the meningococcal serogroup C conjugate vaccine. Federal District, Brazil.
| Age | All cases |
Serogroup C |
Serogroup B |
||||||
|---|---|---|---|---|---|---|---|---|---|
| 2009 Ratea (cases) |
2011 Ratea (cases) |
Variation % |
2009 Ratea (cases) |
2011 Ratea (cases) |
Variation % |
2009 Ratea (cases) |
2011 Ratea (cases) |
Variation % |
|
| <2 | 23.6 (21) | 7.9 (6) | −66.5 | 12.4 (11) | 2.6 (2) | −79.0 | 2.2 (2) | 2.6 (2) | +18.2 |
| 2 | 13.5 (6) | 2.7 (1) | −80.0 | 6.8 (3) | 0.0 (0) | −100 | 0 (0) | 0.0 (0) | – |
| 3 | 9.0 (4) | 7.8 (3) | −13.3 | 4.5 (2) | 0.0 (0) | −100 | 2.3 (1) | 0.0 (0) | −100 |
| 4 | 15.9 (7) | 5.0 (2) | −68.5 | 13.6 (6) | 2.5 (1) | −81.6 | 0 (0) | 0.0 (0) | – |
| 5–19 | 1.6 (11) | 0.8 (5) | −50.0 | 0.1 (1) | 0.3 (2) | +200 | 0.1 (1) | 0.0 (0) | −100 |
| ≥20 | 0.9 (15) | 0.2 (4) | −77.8 | 0.2 (4) | 0.1 (1) | −50.0 | 0 (0) | 0.0 (0) | – |
| Total | 2.5 (64) | 0.8 (21) | −68.0 | 1.0 (27) | 0.2 (6) | −80.0 | 0.2 (4) | 0.1 (2) | −50.0 |
a
Average annual incidence rate per 100,000 inhabitants, and number of cases in parentheses.